Page last updated: 2024-11-03

rabeprazole and Rhabdomyolysis

rabeprazole has been researched along with Rhabdomyolysis in 1 studies

Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.

Research Excerpts

ExcerptRelevanceReference
"Polymyositis occurring in patients treated with omeprazole has been signalled as a possible adverse drug reaction (ADR) by the New Zealand Intensive Medicines Monitoring Programme (IMMP) and the WHO Collaborating Centre for International Drug Monitoring: the Uppsala Monitoring Centre (UMC)."4.83Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? ( Clark, DW; Strandell, J, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clark, DW1
Strandell, J1

Reviews

1 review available for rabeprazole and Rhabdomyolysis

ArticleYear
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors;

2006